tgindex
Pharmacy Box
@Pharmacistsworlddанглийский
Последний пост
29 мая 2025 г.
Последнее чтение
13 авг.
Постов за неделю
0
Всего постов
20
Тип
открытый
Язык
английский
В каталоге с
13 авг.
Подписчики
10 172
−4 за 5 дн.
Сутки
−1
−0,01%
Неделя
 
Месяц
 
Просмотров на пост
7 335
20 постов
Вовлечённость
72,1%
к подписчикам
Постов в день
0,0
всего 20
Упоминаний
1
каналов
Охват размещения
оценка
1/24сутки в ленте
1/48двое суток
1/72трое суток

Оценка по просмотрам недавних постов: пост набирает почти всё за первые сутки.

Посты

  • без подписи

  • New Micromedex and Lexiccomp Accounts 💊🩺📋 Micromedex Passwords (2024-2025) Drug Info: 7C6ven Interactions: vpXETY IV Compatibility: 4usEMN Pediatric: NMhGmN Neofax: N8XwaJ

  • اسعد ان اشارككم بانطلاق مشروعي التقني FlowPath والذي من خلاله تستطيع ان تحوّل فكرة مشروعك الرقمي لواقع ونجاح ملموس ✅ https://x.com/bandaralsaqry/status/1899487403191976154?s=46 https://x.com/flowpath_sa/status/1899485755254124662?s=46

  • Medications affect electrolytes absorption

  • The U.S. Food and Drug Administration (FDA) has granted approval for Merilog (insulin-aspart-szjj) as the first biosimilar to Novolog (insulin aspart). This approval marks a significant milestone in the development of biosimilar insulin products. It is important to note that Merilog represents the fourth biosimilar to be approved for insulin analogs, following: - Basaglar (a biosimilar of Lantus [insulin glargine]) - Admelog (a biosimilar of Humalog [insulin lispro]) - Truapi (a biosimilar of NovoRapid [insulin aspart]) This development underscores the ongoing advancements in biosimilar therapies, providing additional treatment options for patients requiring insulin therapy. https://www.fda.gov/news-events/press-announcements/fda-approves-first-rapid-acting-insulin-biosimilar-product-treatment-diabetes

  • Antihypertensive Doses & SE

  • Initiation & sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum

  • Initiation & sequencing of guideline-directed medical therapy for heart failure across the ejection fraction spectrum

  • Management of AF in HFrEF ●Unstable> ECV and maintain rhythm with PV ablation or amiodarone ●Stable> Rate control Last step if Rate and Rhythm control failed> AVN ablation Rhythm control > ECV, PV ablation, amiodarone Rate control> BB, Digoxin, amiodarone, AVN ablation

  • Diuretics in AHF: 1.loop diuretics,if refractory> 2.combine with thiazide,if refractory> 3.add dopamine,dobutamine, milrinone 4. Ultrafiltration or hemodialysis(coexist renal failure) In case of low k+>add spironolactone In case of alkalosis>add acetazolamide From Braunwald

  • https://x.com/bandaralsaqry/status/1869072018693603758?s=46

  • Join us tomorrow to know more about the role of pharmacists in supply chain management https://x.com/bandaralsaqry/status/1868708009393983862?s=46

  • Cholesterol management of ASCVD risk reduction

  • Comparison of Aminoglycosides

  • SGLT-2 inhibitors in CKD

  • без подписи

  • Antithrombotic Therapy - Indications and Dosage

  • Management of low-dose Methotrexate toxicity

  • ESGE guidelines on the management of lower GI bleeding

  • 29 сент. 2024 г.11,3 тыс751

    Statins dose adjustment in CKD Atorvastatin is the lower renal elimination agent